4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol

• ChemBase ID: 719
• Molecular Formular: C18H23NO3
• Molecular Mass: 301.38012
• Monoisotopic Mass: 301.1677936
• SMILES: Oc1cc(CCNC(CCc2ccc(O)cc2)C)ccc1O
• Canonical SMILES: CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O
• InChI: InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
• InChIKey: JRWZLRBJNMZMFE-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
• IUPAC Traditional name: dobutamine
• Brand Name: Dobutamina [INN-Spanish]; Dobutamine Hcl; Dobutamine Hcl in Dextrose 5%; Dobutamine Hydrochloride; Dobutamine [Usan:Ban:Inn]; Dobutamine [Usan]; Dobutaminum [INN-Latin]; Dobutrex; Inotrex; Racemic-Dobutamine
• Synonyms: Dobutamine

Database IDs

• CAS Number: 34368-04-2
• PubChem SID: 160964182; 46505241
• PubChem CID: 36811

CALCULATED PROPERTIES

JChem

• Acid pKa: 10.141794
• H Acceptors: 4
• H Donor: 4
• LogD (pH = 5.5): 0.55885684
• LogD (pH = 7.4): 1.1584939
• Log P: 2.6162553
• Molar Refractivity: 88.3911 cm^3
• Polarizability: 34.158314 Å^3
• Polar Surface Area: 72.72 Å^2
• Rotatable Bonds: 7
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 2.97
• LOG S: -4.34
• Solubility (Water): 1.37e-02 g/l

PROPERTIES

Physical Property

• Hydrophobicity(logP): 3.6

DETAILS

DrugBank - DB00841

• Drug Groups: approved
• Description: A beta-2 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. [PubChem]
• Indication: For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures
• Pharmacology: Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
• Affected Organisms: Humans and other mammals
• Half Life: 2 minutes
• Elimination: In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.
• External Links: Wikipedia; RxList; Drugs.com